CTOs on the Move

Newlink Genetics

www.newlinkgenetics.com

 
NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Aurobindo Pharma Limited

Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India.

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.

Hitech Air Conditioning Inc

Hitech Air Conditioning Inc is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.

Ambrilia Biopharma

Ambrilia Biopharma Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.